The Ministry of Health is advising the public that three separate recalls have been issued for semaglutide injection products supplied to the Bermuda market. These recalls relate to product impurities, incorrect dose display, and packaging errors that may result in patients receiving the wrong dose.
All pharmacies and medical warehouses in Bermuda have been formally notified.
Semaglutide is a prescription medication used in adults to improve blood‑glucose control and, in some cases, support weight‑management. Accurate dosing is essential to ensure safe and effective treatment.
- Novo Nordisk Canada Inc. — Incorrect Pen in Package
- Product: Semaglutide Injection (4 mg/3 mL)
- DIN: 02540258
- Lot: LP1107
- Expiry: August 31, 2026
- Issue: Incorrect pen placed inside the carton
- Risk: Wrong dose delivery due to mismatched pen and packaging
- Manufacturer: Novo Nordisk Canada Inc.
Receiving the incorrect pen may result in under‑dosing, over‑dosing, interrupted treatment, or confusion for new users.
2. Dr. Reddy’s Laboratories Canada Inc. — Impurity Out of Specification
An impurity is out of specification in all lots of the affected products.
Affected Products
Semaglutide Injection — 1.34 mg/mL (Solution)
- DIN: 02567806
- Lots: 7000544, 7000545, 7000546
- DIN: 02567814
- Lots: 7000542, 7000543, 7000624, 7000628, 7000629
Patients should verify whether their product is affected and consult their healthcare provider before discontinuing use.
3. Apotex Inc. — Apo‑Semaglutide Incorrect Dose Display
The affected lot may display a 2 mg dose in the dose window and deliver a 2 mg dose instead of the expected 0.25 mg or 0.5 mg dose.
Affected Product
- Brand: Apotex Inc.
- Product: Apo‑Semaglutide (2 mg/pen)
- DIN: 02568020
- Strength: 0.68 mg/mL
- Lot: 7000599A
- Issue: Incorrect dose display and incorrect dose delivery
This may lead to significant under‑ or over‑dosing for patients following titration schedules.
Guidance for Patients
- Do not use any affected product until you have verified the lot number and confirmed whether your supply is part of the recall.
- Return affected products to the pharmacy where they were purchased for replacement, alternative supply, and proper disposal.
- Consult your healthcare provider before discontinuing treatment or if you have concerns about dosing accuracy or adverse effects.
- If you are unsure whether your medication is affected, contact your pharmacy directly.
- Patients who received semaglutide dispensed into vials or alternative packaging should note that the pharmacy name will be printed on the label and should contact that pharmacy to confirm whether their supply is affected.
Minister of Health, Kim Wilson, said,“Ensuring the accuracy and safety of medications used by our community is essential. While these recalls stem from manufacturer quality and packaging issues, we are acting quickly to make sure patients and healthcare providers have clear information. Anyone who believes they may have received an affected product should contact their pharmacist immediately. Our healthcare teams are prepared to support patients and ensure continuity of safe treatment.”
The Ministry of Health will continue to monitor updates from manufacturers and international regulatory partners. Any new information will be shared with the public promptly.
